1. In Vivo
  2. >>New Science

Science Matters: Harnessing The Inherent Power Of MAIT Cells

 
• By Mark Ratner

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.  

• Source: Shutterstock

A publication in the May 25th issue of Science Translational Medicine (STM) suggests that gut microbiota may activate a type of unconventional T cell called MAIT (mucosal-associated invariant T cell) in cancer patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). The paper suggests a link between the presence of MAIT cells, as well as another so-called unconventional T cell, and reduced risk of graft-versus-host disease (GVHD), a serious complication of allogeneic transplantation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Science

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Podcast: Heranova CMO Advocates For Endometriosis Awareness: “Pain Is Not Normal”

 
• By Anabel Costa-Ferreira

Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.

BPGbio: Fusing Patient-Driven Innovation With Causal AI

 
• By David Wild

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

Taking The Temperature Of UK Biotech 2025

 
• By Jo Shorthouse

With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.